Ekso Bionics’ exoskeleton received a final payment determination from the Centers for Medicare and Medicaid Services, paving the way to faster rehabilitation for more patients.

People suffering from multiple sclerosis will now be able to receive rehabilitative therapy with the EksoNR system.

While the Federal Accounting Standards Board has basically ruled out the kinds of limited partnerships Elan for years used to finance its R&D off its income statement, a new set of deals show just how Elan is using deals with biotechs and other drug delivery companies to both supplement its research program and spare its P&L.